VOS DISCOVERY

What VOS DISCOVERY does

VOS Discovery is a Vietnam-based life sciences company operating in the organoid technology space. It runs a B2B contract research organization (CRO) that uses patient-derived and disease-specific organoid models to deliver drug discovery, immuno-oncology, infectious disease, and dermatology/cosmetics testing services for pharmaceutical, biotechnology, cosmetics, food ingredients, and academic oncology research customers.

The company's core technology is organized around two pillars. The ODISEI platform is a service framework subdivided into ODISEI ONC (oncology), ODISEI VIR (virology/infectious disease), and ODISEI SKIN (dermatology and cosmetics) applications, supporting translational research and preclinical testing workflows. The OrganoEZ product line comprises proprietary organoid culture consumables — media, proteins, and extracellular matrix (ECM) components — that the company sells alongside its services, creating a paired reagent-and-service revenue model.

VOS Discovery monetizes through custom-priced CRO project contracts and direct reagent sales, with go-to-market conducted via its website, LinkedIn, YouTube, and industry events. The company is privately held, headquartered in Ho Chi Minh City with a secondary office in Hanoi, and operates with a team of approximately 20 employees. No external funding rounds or revenue figures have been disclosed in the input data.

Name

VOS DISCOVERY

Legal name

VOS Discovery

Website

https://vosdiscovery.vn

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

VOS Discovery is a Vietnam-based organoid technology CRO that delivers preclinical drug discovery, immuno-oncology, infectious disease, and dermatology testing services, and sells proprietary OrganoEZ culture reagents, to pharmaceutical, biotech, cosmetics, and academic research customers.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAGAAAB

Preclinical CROs (Discovery/Pharmacology/DMPK)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Research Organizations (CRO)

SECONDARYHLAGAAAL

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Research Organizations (CRO)

SECONDARYHLAAAIAI

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

• Organoid technology
• Drug discovery services
• Immuno-oncology testing
• Biotech contract research
• Organoid culture products

Headquarters

HQ city

Ho Chi Minh City

HQ country

Vietnam

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. CRO Services - Drug Discovery: Contract research organization services providing organoid-based drug efficacy and toxicity evaluation for pharmaceutical and biotech companies. Services include drug screening, preclinical testing, and therapeutic response prediction.
2. CRO Services - Immuno-Oncology: Specialized CRO services evaluating cancer treatment effectiveness using co-culture models of cancer organoids and immune cells, providing insights into tumor-immune interactions.
3. OrganoEZ Product Sales: Sale of organoid culture products including media, extracellular matrix (ECM), and growth factor proteins for research laboratories and biotech companies.
4. Customized Lab Services: End-to-end laboratory services specializing in comprehensive cell experiment workflows, tailored to specific client research requirements.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

VOS Discovery operates as a contract research organization (CRO) providing organoid-based testing services and products for drug discovery, disease modeling, and immuno-oncology applications. The company offers a proprietary ODISEI platform ecosystem (including ODISEI, ODISEI ONC, ODISEI VIR, ODISEI SKIN) for evaluating drug candidates, alongside the OrganoEZ product line of media, ECM, and protein reagents used to culture 3D organoid models derived from human stem cells.

Product overview

VOS DISCOVERY is a life science company specializing in organoid technology and advanced cell models for drug discovery and biomedical research. The company's product portfolio consists of two main pillars: (1) ODISEI platform ecosystem comprising ODISEI (core drug discovery), ODISEI ONC (immuno-oncology), ODISEI VIR (infectious disease), and ODISEI SKIN (cosmetics/dermatology) for organoid-based evaluation services; and (2) OrganoEZ product line including OrganoEZ Media, OrganoEZ Protein, and OrganoEZ ECM for organoid culture. VOS DISCOVERY operates as a Contract Research Organization (CRO) offering laboratory services including Organoid Culture, Disease Modeling, Drug Discovery, Immuno-Oncology, and Customized Lab Services to pharmaceutical developers, biotechnology companies, and clinical researchers.

Differentiator

Problem solved

Functional benefit

Brands

• OrganoEZ: High-performance ready-to-use formulation designed to support robust growth and long-term maintenance of 3D organoid models derived from human stem cells, including media, proteins, and ECM components
• ODISEI
• ODISEI ONC
• ODISEI VIR
• ODISEI SKIN

Products and services

• ODISEI Drug Discovery Platform

Quantifiable outcome

• Organoid-based drug testing shows high concordance with patient clinical outcomes, significantly exceeding traditional 2D cell cultures or animal models
• +1 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and strategic.

• Hospitals and Medical InstitutionscoreStrategic or Co-development PartnerVOS Discovery collaborates closely with hospitals and medical institutions to access patient tissue samples and clinical data for developing organoid models derived from actual patient materials, supporting disease research and precision medicine applications.
• Research InstitutionscoreStrategic or Co-development PartnerStrategic partnerships with research institutions for advancing organoid technology applications in disease modeling, drug discovery, and precision medicine development.
• Biotechnology OrganizationsstrategicTechnology or IntegrationCollaborations with biotechnology organizations to promote organoid technology applications in disease research, drug development, and precision medicine, leveraging combined expertise and resources.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• InSphero: Swiss organoid and 3D microphysiological system CRO providing drug discovery and toxicity testing services. Directly comparable as an organoid-based preclinical CRO serving pharma and cosmetics clients.
• Hubrecht Organoid Technology: Pioneer of organoid technology from the Hubrecht Institute; licenses organoid know-how and offers organoid-based services for drug discovery and disease modeling. Directly comparable as an organoid-focused CRO with disease modeling capabilities.
• Crown Bioscience: Global preclinical CRO (JSR Life Sciences subsidiary) offering organoid-based oncology services, patient-derived xenografts, and immuno-oncology models. Directly comparable as an enterprise-grade organoid CRO serving pharma biotech.
• OcellO: Netherlands-based organoid CRO offering high-throughput drug screening on patient-derived organoid models. Directly comparable as an organoid-based drug screening CRO.
• DefiniGEN: UK-based organoid CRO specializing in iPSC-derived liver and disease models for drug discovery. Directly comparable as an iPSC-organoid CRO with disease modeling focus.
• Sun Bioscience: Swiss organoid CRO providing organoid-based drug testing and disease modeling services for pharma. Comparable as an organoid CRO with similar service-based GTM.

Broad incumbents

• Corning Life Sciences: Major life science products manufacturer including Matrigel ECM (industry-standard organoid matrix). Comparable as a competitor to VOS's OrganoEZ ECM offering.
• STEMCELL Technologies: Major supplier of organoid culture media, growth factors, and reagents. Comparable as a direct competitor to VOS's OrganoEZ product line (media, ECM, proteins).
• Molecular Devices: Provides organoid imaging and high-content analysis instrumentation used in organoid-based drug screening workflows. Comparable as an enabling technology provider for organoid CROs.

Emerging players

• Cellesce: UK organoid expansion technology company providing standardized organoid production for drug discovery. Adjacent as a specialized organoid technology provider.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/vos-discovery-vn

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VOS DISCOVERY